🎉 M&A multiples are live!
Check it out!

BioCryst Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for BioCryst Pharma and similar public comparables like Pharming, Galapagos, and Vivoryon Therapeutics.

BioCryst Pharma Overview

About BioCryst Pharma

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.


Founded

1991

HQ

United States of America
Employees

580

Website

biocryst.com

Financials

LTM Revenue $483M

LTM EBITDA $16.0M

EV

$2.0B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

BioCryst Pharma Financials

BioCryst Pharma has a last 12-month revenue of $483M and a last 12-month EBITDA of $16.0M.

In the most recent fiscal year, BioCryst Pharma achieved revenue of $451M and an EBITDA of $12.8M.

BioCryst Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See BioCryst Pharma valuation multiples based on analyst estimates

BioCryst Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $331M $451M XXX XXX XXX
Gross Profit $264M $327M XXX XXX XXX
Gross Margin 80% 72% XXX XXX XXX
EBITDA -$116M $12.8M XXX XXX XXX
EBITDA Margin -35% 3% XXX XXX XXX
Net Profit -$247M -$227M XXX XXX XXX
Net Margin -75% -50% XXX XXX XXX
Net Debt $429M $701M XXX XXX XXX

Financial data powered by Morningstar, Inc.

BioCryst Pharma Stock Performance

As of April 15, 2025, BioCryst Pharma's stock price is $7.

BioCryst Pharma has current market cap of $1.5B, and EV of $2.0B.

See BioCryst Pharma trading valuation data

BioCryst Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.0B $1.5B XXX XXX XXX XXX $-0.33

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

BioCryst Pharma Valuation Multiples

As of April 15, 2025, BioCryst Pharma has market cap of $1.5B and EV of $2.0B.

BioCryst Pharma's trades at 4.1x LTM EV/Revenue multiple, and 122.5x LTM EBITDA.

Analysts estimate BioCryst Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for BioCryst Pharma and 10K+ public comps

BioCryst Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.0B XXX XXX XXX
EV/Revenue 4.3x XXX XXX XXX
EV/EBITDA 152.9x XXX XXX XXX
P/E -16.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -36.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get BioCryst Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

BioCryst Pharma Valuation Multiples

BioCryst Pharma's NTM/LTM revenue growth is 21%

BioCryst Pharma's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $0.8M for the same period.

Over next 12 months, BioCryst Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate BioCryst Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for BioCryst Pharma and other 10K+ public comps

BioCryst Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 36% XXX XXX XXX XXX
EBITDA Margin 3% XXX XXX XXX XXX
EBITDA Growth -111% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 24% XXX XXX XXX XXX
Revenue per Employee $0.8M XXX XXX XXX XXX
Opex per Employee $0.8M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 39% XXX XXX XXX XXX
Opex to Revenue 98% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

BioCryst Pharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

BioCryst Pharma M&A and Investment Activity

BioCryst Pharma acquired  XXX companies to date.

Last acquisition by BioCryst Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . BioCryst Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by BioCryst Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About BioCryst Pharma

When was BioCryst Pharma founded? BioCryst Pharma was founded in 1991.
Where is BioCryst Pharma headquartered? BioCryst Pharma is headquartered in United States of America.
How many employees does BioCryst Pharma have? As of today, BioCryst Pharma has 580 employees.
Who is the CEO of BioCryst Pharma? BioCryst Pharma's CEO is Mr. Jon P. Stonehouse.
Is BioCryst Pharma publicy listed? Yes, BioCryst Pharma is a public company listed on NAS.
What is the stock symbol of BioCryst Pharma? BioCryst Pharma trades under BCRX ticker.
When did BioCryst Pharma go public? BioCryst Pharma went public in 1994.
Who are competitors of BioCryst Pharma? Similar companies to BioCryst Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of BioCryst Pharma? BioCryst Pharma's current market cap is $1.5B
What is the current revenue of BioCryst Pharma? BioCryst Pharma's last 12-month revenue is $483M.
What is the current EBITDA of BioCryst Pharma? BioCryst Pharma's last 12-month EBITDA is $16.0M.
What is the current EV/Revenue multiple of BioCryst Pharma? Current revenue multiple of BioCryst Pharma is 4.1x.
What is the current EV/EBITDA multiple of BioCryst Pharma? Current EBITDA multiple of BioCryst Pharma is 122.5x.
What is the current revenue growth of BioCryst Pharma? BioCryst Pharma revenue growth between 2023 and 2024 was 36%.
Is BioCryst Pharma profitable? Yes, BioCryst Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.